[Microvascular and macrovascular complications in children and adolescents with type 1 diabetes mellitus].
Diabetes-related microvascular and macrovascular complications, as retinopathy, nephropathy and neuropathy are life-threatening complications in children and adolescents with type 1 diabetes mellitus (T1DM). Risk factors for the development of complications are longer duration of diabetes, older age and puberty. Further risk factors include smoking, hypertension, higher body mass index and dyslipoproteinaemia. Therefore prevention and screening for complications is an important part in the care of children and adolescents with T1DM. Target levels to reduce the risk of microvascular and macrovascular complications in children and adolescents with T1DM are the following: HbA1c<7.5%, lipids in normal range, blood pressure<90th percentile by age, sex and height, BMI<95th percentile, no smoking and physical activity. Screening for retinopathy and microalbuminuria should start from 11 years with two years diabetes duration and from 9 years with 5 years duration and after 2 years diabetes duration in an adolescent. Thereafter screening should be performed annually. Blood pressure should be measured at least annually. Screening for fasting blood lipids should be performed soon after diagnosis in all children with T1DM aged over 12 years. If normal results are obtained, this should be repeated every 5 years.
Fröhlich-Reiterer
Elke E
EE
Klinische Abteilung für Allgemeine Pädiatrie, Bereich Endokrinologie und Diabetes, Universitätsklinik für Kinder- und Jugendheilkunde, Medizinische Universität Graz, Graz, Austria. elke.froehlich-reiterer@medunigraz.at
Borkenstein
Martin H
MH
D000293:Adolescent; D000367:Age Factors; D001794:Blood Pressure; D015992:Body Mass Index; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000175:diagnosis / Q000453:epidemiology*; D003925:Diabetic Angiopathies / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control; D003928:Diabetic Nephropathies / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control; D003929:Diabetic Neuropathies / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control; D003930:Diabetic Retinopathy / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D008055:Lipids / Q000097:blood; D008403:Mass Screening; D009043:Motor Activity; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects
D006442:Glycated Hemoglobin; D008055:Lipids; C517652:hemoglobin A1c protein, human
Lancet. 1995 Oct 21;346(8982):1080-4
7564792
Diabetes Care. 2003 Jun;26(6):1895-901
12766130
Diabetes Care. 1993 Feb;16(2):434-44
8432214
Diabetes Care. 2005 Mar;28(3):509-13
15735179
Circulation. 2002 Oct 22;106(17):2231-7
12390953
Diabetologia. 1993 Feb;36(2):150-4
8458529
Diabetologia. 2002 May;45(5):711-8
12107752
Diabet Med. 2000 Jul;17(7):495-506
10972578
Eye (Lond). 1999 Apr;13 ( Pt 2):151-9
10450373
Pediatr Diabetes. 2009 Sep;10 Suppl 12:195-203
19754630
Diabetes Care. 2006 Sep;29(9):2072-7
16936155
N Engl J Med. 1993 Sep 30;329(14):977-86
8366922
Am J Med. 1985 May;78(5):785-94
3993659
Lancet. 2003 Jun 14;361(9374):2005-16
12814710
Am J Hypertens. 2003 Oct;16(10):795-800
14553956
J Hypertens. 1991 Feb;9(2):109-14
1849524
Diabetologia. 2003 Jun;46(6):760-5
12774166
Pediatr Diabetes. 2009 May;10(3):168-76
19175900